This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Pharma Sector
The global pharma sector in Q2 2023 witnessed deals worth $51.1 billion, a drop of 20% from the $64 billion deal value recorded in Q1 2023. In terms of deal volume, there was a 28% growth from 178 deals in Q1 2023 to 228 M&A deals in Q2 2023.
The global pharma sector in Q2 2023 witnessed deals worth $51.1 billion, a drop of 20% from the $64 billion deal value recorded in Q1 2023. In terms of deal volume, there was a 28% growth from 178 deals in Q1 2023 to 228 M&A deals in Q2 2023.
Scope
- This report provides an overview of merger and acquisition activity globally in Q2 2023 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q2 2023 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of pharma M&A market - Q2 2023
- Top pharma M&A deals by sector - Q2 2023
- Top pharma M&A deals by geography - Q2 2023
- Top themes driving pharma M&A activity - Q2 2023
- Appendix 1: Deal selection criteria
- Appendix 2: Top themes for 2023 in pharma
- Appendix 3: Thematic research methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bausch & Lomb
- Fine Investment
- Eli Lilly and Co
- Novartis
- Gurnet Point Capital
- Novo Holdings
- Ironwood Pharmaceuticals
- Healthcare Royalty
- Sagard Healthcare
- Bavarian Nordic
- Elliott Investment Management
- Patient Square Capital
- Veritas Capital
- Sobi
- Advent International
- Warburg Pincus
- Votorantim
- La Defense Partners
- Astellas Pharma
- Quest Diagnostics
- Healthwell Acquisition
- Sagaliam Acquisition
- Assertio Holdings
- Amphastar Pharmaceuticals
- Merck & Co
- Novartis
- Boryung Biopharma
- DICE Therapeutics
- Chinook Therapeutics
- Paratek Pharmaceuticals
- VectivBio
- UniQure
- Emergent BioSolutions
- Syneos
- CTI BioPharma
- Baxter Biopharma Solutions
- Hypera
- Hanmi Science
- IVERIC bio
- Haystack Oncology
- Starton Therapeutics
- Enzolytics
- Spectrum Pharmaceuticals
- Eli Lilly (BAQSIMI)
- Prometheus Biosciences
